Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $28.5mm for Intellikine

Executive Summary

Intellikine (therapies for autoimmune diseases, cancer, and inflammation) raised $28.5mm through its second round of venture financing. Novartis Bioventures (which gets a seat on the company's board) led and was joined by new investors US Venture Partners, Biogen Idec, and FinTech Global Capital. Series A backers Abingworth, CMEA Capital, and Sofinnova Ventures also participated. The company could bring in an additional $22.5mm based on the achievement of certain milestones.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies